Clinical Research Directory
Browse clinical research sites, groups, and studies.
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Sponsor: University of Texas Southwestern Medical Center
Summary
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
Official title: STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2025-04-01
Completion Date
2028-10
Last Updated
2025-11-12
Healthy Volunteers
No
Interventions
IMSA101
All enrolled patients to undergo the following treatment: SOC treatment: Nivolumab 480mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: three intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C2D1, C3D1)
Locations (1)
University of Texas Southwestern Medical Center
Dallas, Texas, United States